Researchers from Johns Hopkins University, Wake Forest University and University of East Anglia have found more potential and real heart problems related to Chantix (varenicline), a Pfizer drug that in intended to curb smoking habits. In a review heart problems among 8,216 participants in 14...
Pfizer's stop-smoking drug Chantix (varenicline) can lead to a small increase in cardiovascular problems such as heart attacks for patients who already have cardiovascular disease, U.S. drug regulators said on Thursday. In fact, The Food and Drug Administration (FDA) is changing the label for...
Pfizer has announced that it intends to recall one lot - approximately 19,000 bottles - of Lipitor 40 mg tablets (atorvastatin calcium) distributed in the U.S. The recall stems from one customer report of an uncharacteristic odor related to the bottles in which these lots of Lipitor were...
DiaGenic ASA (OSE:DIAG) and Pfizer Inc [NYSE: PFE] signed an agreement for explorative R&D collaboration to identify biomarkers in early stages of Alzheimer's disease (AD) using DiaGenic's patented gene expression technology and its blood samples from ongoing clinical studies. The companies...
Scientists from the BC Cancer Agency and Pfizer Oncology have published the first results of their three-year research collaboration. The paper, published in the journal Modern Pathology, analyzed the expression of the P-cadherin protein in breast cancer. P-cadherin is involved in controlling...
The World Bank and Pfizer Inc. today announced they will collaborate to improve the healthcare infrastructure, specifically the supply chain, in developing countries, starting with Africa. The novel public-private collaboration will focus on enhanced use of Information and Communication...
The World Bank and Pfizer Inc. today announced they will collaborate to improve the healthcare infrastructure, specifically the supply chain, in developing countries, starting with Africa. The novel public-private collaboration will focus on enhanced use of Information and Communication...
Pfizer, the largest drug maker in the world, disclosed 35 million in payments during the second half of 2009 to doctors who consulted or spoke on behalf of drugs and to the medical centers that tested them, The New York Times reports. This is Pfizer's first disclosure of this nature. "While...
Pfizer Inc. (NYSE: PFE) and DxS (a wholly owned subsidiary of QIAGEN N.V.) (NASDAQ: QGEN; Frankfurt, Prime Standard: QIA) announced that they have entered into an agreement to develop a companion diagnostic test kit for PF-04948568 (CDX-110), an immunotherapy vaccine in development for the...
Jeffrey B. Kindler received the 2010 Catalyst Award, the Glaucoma Research Foundation's highest honor, acknowledging his exemplary leadership in sustaining innovative research and education. Mr. Kindler is Chief Executive Officer and Chairman of the Board of Pfizer Inc., the world's largest...
Jeffrey B. Kindler received the 2010 Catalyst Award, the Glaucoma Research Foundation's highest honor, acknowledging his exemplary leadership in sustaining innovative research and education. Mr. Kindler is Chief Executive Officer and Chairman of the Board of Pfizer Inc., the world's largest...
Pfizer Inc. (Pfizer) and Debiopharm Group™ (Debiopharm) announced today that they have entered into a co-development agreement to conduct a Phase 3 trial of tremelimumab (CP675,206), a fully human anti-CTLA4 monoclonal antibody for the treatment of patients with unresectable, Stage IV melanoma...
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, is reporting Pfizer Inc. has announced that it has decided to discontinue the late-stage study of its lung cancer...
Pfizer Inc. (NYSE: PFE) announced results from studies evaluating neratinib (HKI-272), an investigational, orally administered, pan-ErbB inhibitor, in patients with human epidermal growth factor receptor-2 (HER2, also known as ErbB2) positive breast cancer at the 2009 CTRC-AACR San Antonio...
In connection with the New York Times' recent coverage of hormone therapy1, Pfizer Inc. released important facts and context to respond to the newspaper's account. Pfizer believes the coverage is based on a misleading and selective reading of both the science and history of hormone therapy (HT)...
Pfizer announced that the U.S. Food and Drug Administration (FDA) has approved Revatio® (sildenafil) Injection, an intravenous formulation of Revatio. Revatio is the only FDA-approved phosphodiesterase-5 (PDE5) inhibitor available in both tablet and intravenous formulations.
More...